CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenues:
Total revenues	$ 695	$ 156
Operating expenses:
Research and development	52,614	31,661
General and administrative	10,820	9,103
Total operating expenses	63,434	40,764
Operating loss	(62,739)	(40,608)
Investment and other income, net	8,943	7,800
Net loss	$ (53,796)	$ (32,808)
Basic net loss per common share (in dollars per share)	$ (0.81)	$ (0.56)
Diluted net loss per common share (in dollars per share)	$ (0.81)	$ (0.56)
Shares used in calculating basic net loss per share (in shares)	66,383	58,871
Shares used in calculating diluted net loss per share (in shares)	66,383	58,871
Comprehensive loss:
Net loss	$ (53,796)	$ (32,808)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	254	(1,064)
Comprehensive loss	(53,542)	(33,872)
Product development and licensing agreements
Revenues:
Total revenues	50	2
Contracts and grants
Revenues:
Total revenues	$ 645	$ 154